BC
SRPT icon

Bridgefront Capital’s Sarepta Therapeutics SRPT Stock Holding History

Bridgefront Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
+12,090
New +$229K 0.06% 435
2026
Q1 		– Sell
-9,866
Closed -$212K – 743
2025
Q4 		$212K Buy
+9,866
New +$208K 0.05% 445
2025
Q2 		– Sell
-4,718
Closed -$301K – 837
2025
Q1 		$301K Buy
+4,718
New +$497K 0.09% 394
2024
Q3 		– Sell
-2,100
Closed -$332K – 704
2024
Q2 		$332K Buy
+2,100
New +$270K 0.14% 264
2022
Q4 		– Sell
-2,072
Closed -$229K – 510
2022
Q3 		$229K Buy
+2,072
New +$209K 0.23% 197
2021
Q2 		– Sell
-11,609
Closed -$865K – 885
2021
Q1 		$865K Buy
+11,609
New +$1.07M 0.27% 77

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bridgefront Capital's SRPT Position: Q2 2026 in Review

Bridgefront Capital opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 12,090 shares worth $217K. The stake represents 0.06% of the portfolio and ranks #435 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in SRPT as recently as Q4 2025.

Bridgefront Capital first reported a position in SRPT in Q1 2021 and has held it in 6 quarters since. The position peaked at $865K in Q1 2021. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Bridgefront Capital held 12,090 shares of Sarepta Therapeutics worth $217K as of Q2 2026.
  • Sarepta Therapeutics was a new Bridgefront Capital position in Q2 2026.
  • Sarepta Therapeutics made up 0.06% of Bridgefront Capital's portfolio in Q2 2026, its #435 holding.
  • Bridgefront Capital first reported a position in Sarepta Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • Bridgefront Capital's Sarepta Therapeutics position peaked at $865K in Q1 2021.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.